poisar

Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target

Benzinga Newsdesk

HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and maintains $43 price target.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

KYNB
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — KYNTRA BIO, INC. (KYNB)

    Filed: 2026-08-31 AccNo: 0001193125-26-377059 Size: 212 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    KYNB
  2. Benzinga Newsdesk

    Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan

    Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 million Company accelerated payment of $42.6 million upfront, bringing total payments made to date to $50

    KYNB